Soe77的个人主页 - 老虎社区

Soe77

Soe77

暂无个人介绍

IP属地：未知

94关注

1粉丝

0主题

0勋章

2021-11-17

$WILMAR INTERNATIONAL LIMITED(F34.SI)$All time positive news but stocks still trading under price… Got to hold for the long term✊🏻

2021-11-15

All rite man!👍

Pfizer’s Big Gamble Is Paying Off. Its Stock Is a Good Long-Term Bet.

2021-11-09

👍

Buffett Signals Caution With Berkshire on Stock-Selling Streak

2021-11-19

$Pfizer(PFE)$Once FDA approve the new COVID drug, believe it will score new highs✊🏻

2021-10-28

Ho say liaoz!

Merck raises full-year profit target after cancer drug sales help Q3 beat

2021-11-18

😴

@Moonwalker:$Tesla Motors(TSLA)$by end of November will plummet to $600

2021-11-16

👍

@美股研究社:苹果推出首部韩国电视剧《头脑博士》

2021-11-11

Will make comeback!✊🏻

The shares has been havling since Jun 2021 till now. Especially the news broke that Chinawill have more restrictions on foreign tradingfirms. I strongly believe this stock will regain its grounds once it resolve its regulatory concerns back home…👍👌🏻

Will make comeback!✊🏻

2021-11-09

👍

@寂小桦:$英伟达(NVDA)$最近买的美国大科技股半年call，第一个结出了十万美金的果实🍒

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4092299591527610,"uuid":"4092299591527610","gmtCreate":1629274995060,"gmtModify":1629724031651,"name":"Soe77","pinyin":"soe77","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":94,"tweetSize":12,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.24%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":876183957,"gmtCreate":1637281996126,"gmtModify":1637281996126,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Once FDA approve the new COVID drug, believe it will score new highs✊🏻","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Once FDA approve the new COVID drug, believe it will score new highs✊🏻","text":"$Pfizer(PFE)$Once FDA approve the new COVID drug, believe it will score new highs✊🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876183957","isVote":1,"tweetType":1,"viewCount":334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876059084,"gmtCreate":1637246220782,"gmtModify":1637246220782,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"😴","listText":"😴","text":"😴","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876059084","repostId":"878149502","repostType":1,"repost":{"id":878149502,"gmtCreate":1637161650153,"gmtModify":1637164295965,"author":{"id":"3578144431053530","authorId":"3578144431053530","name":"Moonwalker","avatar":"https://static.tigerbbs.com/09c444fbe99e3975f4bc242d4d531918","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>by end of November will plummet to $600","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>by end of November will plummet to $600","text":"$Tesla Motors(TSLA)$by end of November will plummet to $600","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878149502","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878077449,"gmtCreate":1637131128652,"gmtModify":1637131128743,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/F34.SI\">$WILMAR INTERNATIONAL LIMITED(F34.SI)$</a>All time positive news but stocks still trading under price… Got to hold for the long term✊🏻","listText":"<a href=\"https://laohu8.com/S/F34.SI\">$WILMAR INTERNATIONAL LIMITED(F34.SI)$</a>All time positive news but stocks still trading under price… Got to hold for the long term✊🏻","text":"$WILMAR INTERNATIONAL LIMITED(F34.SI)$All time positive news but stocks still trading under price… Got to hold for the long term✊🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878077449","isVote":1,"tweetType":1,"viewCount":767,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871191520,"gmtCreate":1637033311071,"gmtModify":1637033311071,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871191520","repostId":"873554124","repostType":1,"repost":{"id":873554124,"gmtCreate":1636967183237,"gmtModify":1637016860845,"author":{"id":"3503452965237041","authorId":"3503452965237041","name":"美股研究社","avatar":"https://static.tigerbbs.com/a239c7906133df1f3817d0746a8a0ba1","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"苹果推出首部韩国电视剧《头脑博士》","htmlText":"美股研究社获悉，据新浪科技消息，继奈飞(NFLX.O)推出的《鱿鱼游戏》大热之后，苹果<a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a>&nbsp;(AAPL.O)于本月推出了其首部韩语原创电视剧《头脑博士》，以配合其在韩国推出的Apple TV+流媒体服务。据了解，苹果于11月4日在韩国推出Apple TV+，同日，《头脑博士》在该流媒体服务上首发亮相。然而，目前Apple TV+远远落后于其在韩国的竞争对手奈飞。奈飞多年来一直在提供授权和原创的韩国内容。本文来源：美股研究社，旨在帮助中国投资者理解世界，专注报道美国科技股和中概股，对美股感兴趣的朋友赶紧关注我们","listText":"美股研究社获悉，据新浪科技消息，继奈飞(NFLX.O)推出的《鱿鱼游戏》大热之后，苹果<a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a>&nbsp;(AAPL.O)于本月推出了其首部韩语原创电视剧《头脑博士》，以配合其在韩国推出的Apple TV+流媒体服务。据了解，苹果于11月4日在韩国推出Apple TV+，同日，《头脑博士》在该流媒体服务上首发亮相。然而，目前Apple TV+远远落后于其在韩国的竞争对手奈飞。奈飞多年来一直在提供授权和原创的韩国内容。本文来源：美股研究社，旨在帮助中国投资者理解世界，专注报道美国科技股和中概股，对美股感兴趣的朋友赶紧关注我们","text":"美股研究社获悉，据新浪科技消息，继奈飞(NFLX.O)推出的《鱿鱼游戏》大热之后，苹果$苹果(AAPL)$ (AAPL.O)于本月推出了其首部韩语原创电视剧《头脑博士》，以配合其在韩国推出的Apple TV+流媒体服务。据了解，苹果于11月4日在韩国推出Apple TV+，同日，《头脑博士》在该流媒体服务上首发亮相。然而，目前Apple TV+远远落后于其在韩国的竞争对手奈飞。奈飞多年来一直在提供授权和原创的韩国内容。本文来源：美股研究社，旨在帮助中国投资者理解世界，专注报道美国科技股和中概股，对美股感兴趣的朋友赶紧关注我们","images":[{"img":"https://static.tigerbbs.com/5a6b64d53562ab9e306b20f4b6058c54","width":"688","height":"459"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873554124","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":666,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873751724,"gmtCreate":1636988706024,"gmtModify":1636988706024,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"All rite man!👍","listText":"All rite man!👍","text":"All rite man!👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873751724","repostId":"1136859135","repostType":2,"isVote":1,"tweetType":1,"viewCount":556,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870305226,"gmtCreate":1636586123278,"gmtModify":1636594155994,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Will make comeback!✊🏻","htmlText":"The shares has been havling since Jun 2021 till now. Especially the news broke that Chinawill have more restrictions on foreign tradingfirms. I strongly believe this stock will regain its grounds once it resolve its regulatory concerns back home…👍👌🏻","listText":"The shares has been havling since Jun 2021 till now. Especially the news broke that Chinawill have more restrictions on foreign tradingfirms. I strongly believe this stock will regain its grounds once it resolve its regulatory concerns back home…👍👌🏻","text":"The shares has been havling since Jun 2021 till now. Especially the news broke that Chinawill have more restrictions on foreign tradingfirms. I strongly believe this stock will regain its grounds once it resolve its regulatory concerns back home…👍👌🏻","images":[{"img":"https://static.tigerbbs.com/8e21674cfa37a10b9a3920b1b93461e5","width":"1170","height":"2142"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870305226","isVote":1,"tweetType":1,"viewCount":726,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844844604,"gmtCreate":1636419143637,"gmtModify":1636419167940,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844844604","repostId":"842956653","repostType":1,"repost":{"id":842956653,"gmtCreate":1636127116289,"gmtModify":1636410656755,"author":{"id":"3452465123342235","authorId":"3452465123342235","name":"寂小桦","avatar":"https://static.laohu8.com/0e07cce79084c04d3561102b1003d0fd","crmLevel":9,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$</a>最近买的美国大科技股半年call，第一个结出了十万美金的果实🍒","listText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$</a>最近买的美国大科技股半年call，第一个结出了十万美金的果实🍒","text":"$英伟达(NVDA)$最近买的美国大科技股半年call，第一个结出了十万美金的果实🍒","images":[{"img":"https://static.tigerbbs.com/c9731dd1e4546b39d7693c85d74a89ea","width":"1170","height":"2532"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842956653","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":458,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844844010,"gmtCreate":1636419088577,"gmtModify":1636419166570,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844844010","repostId":"1190184675","repostType":4,"isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854326061,"gmtCreate":1635421667514,"gmtModify":1635421667628,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ho say liaoz!","listText":"Ho say liaoz!","text":"Ho say liaoz!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854326061","repostId":"2178265612","repostType":4,"repost":{"id":"2178265612","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck &amp; Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":593,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":878077449,"gmtCreate":1637131128652,"gmtModify":1637131128743,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/F34.SI\">$WILMAR INTERNATIONAL LIMITED(F34.SI)$</a>All time positive news but stocks still trading under price… Got to hold for the long term✊🏻","listText":"<a href=\"https://laohu8.com/S/F34.SI\">$WILMAR INTERNATIONAL LIMITED(F34.SI)$</a>All time positive news but stocks still trading under price… Got to hold for the long term✊🏻","text":"$WILMAR INTERNATIONAL LIMITED(F34.SI)$All time positive news but stocks still trading under price… Got to hold for the long term✊🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878077449","isVote":1,"tweetType":1,"viewCount":767,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873751724,"gmtCreate":1636988706024,"gmtModify":1636988706024,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"All rite man!👍","listText":"All rite man!👍","text":"All rite man!👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873751724","repostId":"1136859135","repostType":2,"repost":{"id":"1136859135","pubTimestamp":1636947003,"share":"https://www.laohu8.com/m/news/1136859135?lang=&edition=full","pubTime":"2021-11-15 11:30","market":"us","language":"en","title":"Pfizer’s Big Gamble Is Paying Off. Its Stock Is a Good Long-Term Bet.","url":"https://stock-news.laohu8.com/highlight/detail?id=1136859135","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson &amp; Johnson (JNJ) and Eli Lilly (LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.<img src=\"https://static.tigerbbs.com/7b64a90a2587bba33128c2a9cf35a596\" tg-width=\"961\" tg-height=\"647\" width=\"100%\" height=\"auto\">The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer’s Big Gamble Is Paying Off. Its Stock Is a Good Long-Term Bet.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer’s Big Gamble Is Paying Off. Its Stock Is a Good Long-Term Bet.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 11:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=newsviewer_click><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.marketwatch.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.marketwatch.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1136859135","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":556,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844844010,"gmtCreate":1636419088577,"gmtModify":1636419166570,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844844010","repostId":"1190184675","repostType":4,"repost":{"id":"1190184675","pubTimestamp":1636384600,"share":"https://www.laohu8.com/m/news/1190184675?lang=&edition=full","pubTime":"2021-11-08 23:16","market":"us","language":"en","title":"Buffett Signals Caution With Berkshire on Stock-Selling Streak","url":"https://stock-news.laohu8.com/highlight/detail?id=1190184675","media":"Bloomberg","summary":"(Bloomberg) -- Warren Buffett is signaling wariness with the soaring stock market as the billionaire","content":"<p>(Bloomberg) -- Warren Buffett is signaling wariness with the soaring stock market as the billionaire investor extends a selling streak.</p>\n<p>Buffett’s Berkshire Hathaway Inc. was a net seller of equities for the fourth straight quarter, a trend not seen in data going back to 2008. The company ended up selling almost $2 billion more in stocks than it purchased during the period, adding to a cash pile that climbed to a record $149.2 billion.</p>\n<p>The selling streak indicates Buffett has struggled to find bargains with the stock market hitting all-time highs. A big, splashy acquisition also eluded the conglomerate, as the 91-year old and his investing deputies confronted a combination of sky-high price tags and fierce competition from the wave of special purpose acquisition companies.</p>\n<p>“The big issue here is that Berkshire was a net seller of stocks again this quarter,” Jim Shanahan, an analyst with Edward Jones, said in a telephone interview. “That’s the primary culprit” of the cash pile continuing to rise.</p>\n<p>Berkshire’s sales appear to have largely come from cutting holdings in banks, insurance and financial investments, according to its third-quarter regulatory filing released Saturday. Berkshire has been paring certain stocks in recent periods, spending the second quarter trimming its investment in General Motors Co. and pulling back on some of its pharmaceutical bets. The company is set to release its third-quarter stock tweaks later this month.</p>\n<p>While Buffett’s been a consistent net seller these past four quarters, those sales have been relatively small compared with the massive size of his stock portfolio. Over the past nine months, he’s sold almost $7 billion more of stocks than he’s bought, roughly 2.2% of the fair value of Berkshire’s stock portfolio at the end of September.</p>\n<p>Buffett warned investors in May that Berkshire might not have much luck striking deals as SPACs gripped the market -- though he also predicted the boom probably wouldn’t last. Compounding the challenge, his most recent big acquisition, the $37 billion deal for Precision Castparts five years ago, resulted in a writedown that Buffett laid squarely at his own door.</p>\n<p>Berkshire isn’t alone in extending a cash pile amid the pandemic. Amazon.com Inc., Google-parent Alphabet Inc. and American Airlines Group Inc. were among companies that amassed significant holdings during the health crisis in a step analysts have said would likely lead to some acquisitions.</p>\n<p>And the rising cash pile is better than the alternative in the eyes of investors including Cheviot Value Management’s Darren Pollock. Even though Buffett’s cash pile still increased to a record despite the $7.6 billion of buybacks in the third quarter, Pollock says it’s a good sign about the health of Berkshire.</p>\n<p>“We’re happy with it because the alternative is that cash isn’t growing as much and that means that Berkshire’s operating companies aren’t of as high quality as we thought,” said Pollock, whose Cheviot owns shares in Berkshire. “To see that the cash is rising, to see that he’s deploying so much in one avenue which happens to be buybacks -- it’s not acquisitions -- but it’s being spent in a productive way, it’s so much better than the alternative of seeing that cash stabilize or decline without other large acquisitions.”</p>\n<p>Here are some other key takeaways from Berkshire’s third-quarter earnings on Saturday:</p>\n<p>Berkshire Appetite</p>\n<p>Buffett has increasingly leaned on share buybacks as one way to deploy billions of dollars. He’s spent about $51 billion on stock buybacks since a policy tweak in 2018, outpacing the $31 billion used to purchase shares of Apple Inc., Berkshire’s largest stock bet.</p>\n<p>In the third quarter, Berkshire bought back $7.6 billion of stock, surpassing the $6 billion of shares repurchased in the previous period.</p>\n<p>BNSF’s Record</p>\n<p>Record profit at Berkshire’s railroad, BNSF, and strong earnings from its energy businesses helped raise operating profit by 18% at the conglomerate during the third quarter.</p>\n<p>That also aided in offsetting a painful quarter for Berkshire’s insurers. Those businesses reported an underwriting loss that widened to $784 million amid heightened catastrophe costs and worsening claims trends at auto insurer Geico.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buffett Signals Caution With Berkshire on Stock-Selling Streak</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuffett Signals Caution With Berkshire on Stock-Selling Streak\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-08 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/buffett-signals-caution-berkshire-stock-140819517.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Warren Buffett is signaling wariness with the soaring stock market as the billionaire investor extends a selling streak.\nBuffett’s Berkshire Hathaway Inc. was a net seller of equities ...</p>\n\n<a href=\"https://finance.yahoo.com/news/buffett-signals-caution-berkshire-stock-140819517.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","BRK.B":"伯克希尔B"},"source_url":"https://finance.yahoo.com/news/buffett-signals-caution-berkshire-stock-140819517.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190184675","content_text":"(Bloomberg) -- Warren Buffett is signaling wariness with the soaring stock market as the billionaire investor extends a selling streak.\nBuffett’s Berkshire Hathaway Inc. was a net seller of equities for the fourth straight quarter, a trend not seen in data going back to 2008. The company ended up selling almost $2 billion more in stocks than it purchased during the period, adding to a cash pile that climbed to a record $149.2 billion.\nThe selling streak indicates Buffett has struggled to find bargains with the stock market hitting all-time highs. A big, splashy acquisition also eluded the conglomerate, as the 91-year old and his investing deputies confronted a combination of sky-high price tags and fierce competition from the wave of special purpose acquisition companies.\n“The big issue here is that Berkshire was a net seller of stocks again this quarter,” Jim Shanahan, an analyst with Edward Jones, said in a telephone interview. “That’s the primary culprit” of the cash pile continuing to rise.\nBerkshire’s sales appear to have largely come from cutting holdings in banks, insurance and financial investments, according to its third-quarter regulatory filing released Saturday. Berkshire has been paring certain stocks in recent periods, spending the second quarter trimming its investment in General Motors Co. and pulling back on some of its pharmaceutical bets. The company is set to release its third-quarter stock tweaks later this month.\nWhile Buffett’s been a consistent net seller these past four quarters, those sales have been relatively small compared with the massive size of his stock portfolio. Over the past nine months, he’s sold almost $7 billion more of stocks than he’s bought, roughly 2.2% of the fair value of Berkshire’s stock portfolio at the end of September.\nBuffett warned investors in May that Berkshire might not have much luck striking deals as SPACs gripped the market -- though he also predicted the boom probably wouldn’t last. Compounding the challenge, his most recent big acquisition, the $37 billion deal for Precision Castparts five years ago, resulted in a writedown that Buffett laid squarely at his own door.\nBerkshire isn’t alone in extending a cash pile amid the pandemic. Amazon.com Inc., Google-parent Alphabet Inc. and American Airlines Group Inc. were among companies that amassed significant holdings during the health crisis in a step analysts have said would likely lead to some acquisitions.\nAnd the rising cash pile is better than the alternative in the eyes of investors including Cheviot Value Management’s Darren Pollock. Even though Buffett’s cash pile still increased to a record despite the $7.6 billion of buybacks in the third quarter, Pollock says it’s a good sign about the health of Berkshire.\n“We’re happy with it because the alternative is that cash isn’t growing as much and that means that Berkshire’s operating companies aren’t of as high quality as we thought,” said Pollock, whose Cheviot owns shares in Berkshire. “To see that the cash is rising, to see that he’s deploying so much in one avenue which happens to be buybacks -- it’s not acquisitions -- but it’s being spent in a productive way, it’s so much better than the alternative of seeing that cash stabilize or decline without other large acquisitions.”\nHere are some other key takeaways from Berkshire’s third-quarter earnings on Saturday:\nBerkshire Appetite\nBuffett has increasingly leaned on share buybacks as one way to deploy billions of dollars. He’s spent about $51 billion on stock buybacks since a policy tweak in 2018, outpacing the $31 billion used to purchase shares of Apple Inc., Berkshire’s largest stock bet.\nIn the third quarter, Berkshire bought back $7.6 billion of stock, surpassing the $6 billion of shares repurchased in the previous period.\nBNSF’s Record\nRecord profit at Berkshire’s railroad, BNSF, and strong earnings from its energy businesses helped raise operating profit by 18% at the conglomerate during the third quarter.\nThat also aided in offsetting a painful quarter for Berkshire’s insurers. Those businesses reported an underwriting loss that widened to $784 million amid heightened catastrophe costs and worsening claims trends at auto insurer Geico.","news_type":1},"isVote":1,"tweetType":1,"viewCount":606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876183957,"gmtCreate":1637281996126,"gmtModify":1637281996126,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Once FDA approve the new COVID drug, believe it will score new highs✊🏻","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Once FDA approve the new COVID drug, believe it will score new highs✊🏻","text":"$Pfizer(PFE)$Once FDA approve the new COVID drug, believe it will score new highs✊🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876183957","isVote":1,"tweetType":1,"viewCount":334,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854326061,"gmtCreate":1635421667514,"gmtModify":1635421667628,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ho say liaoz!","listText":"Ho say liaoz!","text":"Ho say liaoz!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854326061","repostId":"2178265612","repostType":4,"repost":{"id":"2178265612","pubTimestamp":1635421212,"share":"https://www.laohu8.com/m/news/2178265612?lang=&edition=full","pubTime":"2021-10-28 19:40","market":"us","language":"en","title":"Merck raises full-year profit target after cancer drug sales help Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2178265612","media":"Reuters","summary":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong de","content":"<p>(Reuters) -Merck &amp; Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.</p>\n<p>Sales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.</p>\n<p>The company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.</p>\n<p>The forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.</p>\n<p>Merck's shares rose 2.4% before the opening bell.</p>\n<p><img src=\"https://static.tigerbbs.com/b7cb17007b56605e17fcfbaa50ab19e1\" tg-width=\"883\" tg-height=\"598\" width=\"100%\" height=\"auto\"></p>\n<p>The company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.</p>\n<p>Net income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.</p>\n<p>Excluding <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.</p>\n<p>Sales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.</p>\n<p>Sales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck raises full-year profit target after cancer drug sales help Q3 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck raises full-year profit target after cancer drug sales help Q3 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-profit-jumps-strong-vaccine-104112033.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2178265612","content_text":"(Reuters) -Merck & Co Inc raised its full-year adjusted profit forecast on Thursday, after strong demand for its blockbuster cancer drug Keytruda and recovery in sales of its non-COVID-19 vaccines helped it beat third-quarter profit estimates.\nSales of vaccines and physician-administered drugs have started to improve as hospitals and clinics adapt to the pandemic, helping Merck, which gets two-thirds of its revenue from drugs that need to be administered at the doctor's office.\nThe company now expects full-year adjusted profit to be between $5.65 and $5.70 per share, up from its prior expectations of $5.47 to $5.57.\nThe forecast did not include any potential contribution from Merck's oral COVID-19 drug candidate, molnupiravir. That could give Merck's profit forecast room to grow if the drug gets U.S. authorization this year.\nMerck's shares rose 2.4% before the opening bell.\n\nThe company earlier this month reported data that showed molnupiravir could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck and partner Ridgeback Biotherapeutics have applied for emergency use authorization of the drug, which could potentially change how COVID-19 is treated.\nNet income attributable to Merck rose to $4.57 billion, or $1.81 per share in the third-quarter, from $2.94 billion, or $1.16 per share, a year earlier.\nExcluding one-time items, Merck earned $1.75 per share, beating estimates of $1.55 per share.\nSales from Gardasil, a vaccine to prevent cervical cancer due to human papillomavirus, jumped nearly 68% to $1.99 billion, beating analysts' average estimate of $1.35 billion, according to IBES data from Refinitiv.\nSales from cancer drug Keytruda, which is on track to become the world's best-selling treatment by 2023, rose 22% to $4.53 billion, beating estimates of $4.31 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":593,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876059084,"gmtCreate":1637246220782,"gmtModify":1637246220782,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"😴","listText":"😴","text":"😴","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876059084","repostId":"878149502","repostType":1,"repost":{"id":878149502,"gmtCreate":1637161650153,"gmtModify":1637164295965,"author":{"id":"3578144431053530","authorId":"3578144431053530","name":"Moonwalker","avatar":"https://static.tigerbbs.com/09c444fbe99e3975f4bc242d4d531918","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>by end of November will plummet to $600","listText":"<a href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a>by end of November will plummet to $600","text":"$Tesla Motors(TSLA)$by end of November will plummet to $600","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878149502","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871191520,"gmtCreate":1637033311071,"gmtModify":1637033311071,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871191520","repostId":"873554124","repostType":1,"repost":{"id":873554124,"gmtCreate":1636967183237,"gmtModify":1637016860845,"author":{"id":"3503452965237041","authorId":"3503452965237041","name":"美股研究社","avatar":"https://static.tigerbbs.com/a239c7906133df1f3817d0746a8a0ba1","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"苹果推出首部韩国电视剧《头脑博士》","htmlText":"美股研究社获悉，据新浪科技消息，继奈飞(NFLX.O)推出的《鱿鱼游戏》大热之后，苹果<a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a>&nbsp;(AAPL.O)于本月推出了其首部韩语原创电视剧《头脑博士》，以配合其在韩国推出的Apple TV+流媒体服务。据了解，苹果于11月4日在韩国推出Apple TV+，同日，《头脑博士》在该流媒体服务上首发亮相。然而，目前Apple TV+远远落后于其在韩国的竞争对手奈飞。奈飞多年来一直在提供授权和原创的韩国内容。本文来源：美股研究社，旨在帮助中国投资者理解世界，专注报道美国科技股和中概股，对美股感兴趣的朋友赶紧关注我们","listText":"美股研究社获悉，据新浪科技消息，继奈飞(NFLX.O)推出的《鱿鱼游戏》大热之后，苹果<a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a>&nbsp;(AAPL.O)于本月推出了其首部韩语原创电视剧《头脑博士》，以配合其在韩国推出的Apple TV+流媒体服务。据了解，苹果于11月4日在韩国推出Apple TV+，同日，《头脑博士》在该流媒体服务上首发亮相。然而，目前Apple TV+远远落后于其在韩国的竞争对手奈飞。奈飞多年来一直在提供授权和原创的韩国内容。本文来源：美股研究社，旨在帮助中国投资者理解世界，专注报道美国科技股和中概股，对美股感兴趣的朋友赶紧关注我们","text":"美股研究社获悉，据新浪科技消息，继奈飞(NFLX.O)推出的《鱿鱼游戏》大热之后，苹果$苹果(AAPL)$ (AAPL.O)于本月推出了其首部韩语原创电视剧《头脑博士》，以配合其在韩国推出的Apple TV+流媒体服务。据了解，苹果于11月4日在韩国推出Apple TV+，同日，《头脑博士》在该流媒体服务上首发亮相。然而，目前Apple TV+远远落后于其在韩国的竞争对手奈飞。奈飞多年来一直在提供授权和原创的韩国内容。本文来源：美股研究社，旨在帮助中国投资者理解世界，专注报道美国科技股和中概股，对美股感兴趣的朋友赶紧关注我们","images":[{"img":"https://static.tigerbbs.com/5a6b64d53562ab9e306b20f4b6058c54","width":"688","height":"459"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873554124","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":666,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870305226,"gmtCreate":1636586123278,"gmtModify":1636594155994,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Will make comeback!✊🏻","htmlText":"The shares has been havling since Jun 2021 till now. Especially the news broke that Chinawill have more restrictions on foreign tradingfirms. I strongly believe this stock will regain its grounds once it resolve its regulatory concerns back home…👍👌🏻","listText":"The shares has been havling since Jun 2021 till now. Especially the news broke that Chinawill have more restrictions on foreign tradingfirms. I strongly believe this stock will regain its grounds once it resolve its regulatory concerns back home…👍👌🏻","text":"The shares has been havling since Jun 2021 till now. Especially the news broke that Chinawill have more restrictions on foreign tradingfirms. I strongly believe this stock will regain its grounds once it resolve its regulatory concerns back home…👍👌🏻","images":[{"img":"https://static.tigerbbs.com/8e21674cfa37a10b9a3920b1b93461e5","width":"1170","height":"2142"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870305226","isVote":1,"tweetType":1,"viewCount":726,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844844604,"gmtCreate":1636419143637,"gmtModify":1636419167940,"author":{"id":"4092299591527610","authorId":"4092299591527610","name":"Soe77","avatar":"https://static.tigerbbs.com/0c4bc3a12eb7f3a8247114e51c54b4ff","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844844604","repostId":"842956653","repostType":1,"repost":{"id":842956653,"gmtCreate":1636127116289,"gmtModify":1636410656755,"author":{"id":"3452465123342235","authorId":"3452465123342235","name":"寂小桦","avatar":"https://static.laohu8.com/0e07cce79084c04d3561102b1003d0fd","crmLevel":9,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$</a>最近买的美国大科技股半年call，第一个结出了十万美金的果实🍒","listText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$</a>最近买的美国大科技股半年call，第一个结出了十万美金的果实🍒","text":"$英伟达(NVDA)$最近买的美国大科技股半年call，第一个结出了十万美金的果实🍒","images":[{"img":"https://static.tigerbbs.com/c9731dd1e4546b39d7693c85d74a89ea","width":"1170","height":"2532"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842956653","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":458,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}